James Overell MD was a member of the Neuro-Compass Steering Group until April 2019, when he started a new position as Principal Global Medical Director in the Multiple Sclerosis (MS)/Neuroinflammation group at F. Hoffmann-La Roche.
Between 2005 and 2019, Dr Overell was a Consultant Neurologist with an interest in MS at the Institute of Neurological Sciences in Glasgow, UK. He graduated with distinction in general medicine from Edinburgh Medical School in 1994, and undertook postgraduate training in Edinburgh, North Staffordshire and Glasgow. Dr Overell completed an MSc in Clinical Pharmacology in 1999, and an MD thesis relating to causes of ischaemic stroke in young adults in 2002. He subsequently specialised in inflammatory neurological disorders, specifically MS and inflammatory neuropathies.
Scotland has the highest prevalence of MS in the world, and between 2012 and 2019, Dr Overell led the Glasgow MS Clinical Research Centre, which is now one of the largest clinical research facilities for new MS therapies in the UK. He acted as Principal and Chief Investigator for a variety of pharmaceutical and investigator-led studies of disease-modifying and neuro-protective agents for relapsing–remitting and progressive MS, led a major UK-based observational study examining the use and safety of new monoclonal therapies, and took a major role in a variety of registry-based and prospective observational studies. During this time, he maintained a very busy clinical practice, focusing on disease-modifying treatment for MS, but with a regular commitment to both general outpatient and emergency neurological care. In March 2019, he was awarded an Honorary Clinical Associate Professorship by the University of Glasgow, where he continues to supervise postgraduate projects in MS.
Fees for speaking, consulting or educational grants from Biogen, Genzyme, Merck-Serono, Novartis, and Teva. Employee at F. Hoffmann-La Roche.